‌Free prolactin receptor status in breast cancer

Authors

M Sirati Sabet, F Karami Tehrani,*, M Taghikhani, M Atri
*Corresponding Author: Email: [email protected]

Journal of Inflammatory Diseases:Vol. 4, issue 2; 44-51
Published online:Sep 30, 2000
Article type:Research Article
How to Cite:Sirati Sabet M, Karami Tehrani F, Taghikhani M, Atri M. ‌Free prolactin receptor status in breast cancer. J Inflamm Dis. 2024;4(2):e154711. doi:

Abstract

Abstract Background: Prolactin simulates the development and differentiation of breast cells. This hormon is mediated by its binding to the specific membrane receptor. Objective: To evaluate the free prolactin receptor (PRO-R) status in malignant tumors of the breast. Methods: Free PRO-R was estimated in the membrane of 40 breast cancer tumors by ligand binding assay. Findings: The results indicated that 45% of tumors have specific binding greater than 1% of radioactivity which was defined to be positive for PRO-R. Grade II and III tumors had 54% and 40% PRO-R respectively. 40% of the patients with lymph node involvment and 64% without lymph node involvement were observed to be positive for PRO-R. 40% of premenopauses and 50% of postmenopauses had PRO-R +. Conclusion: Some breast cancer tumors have lymph node involvement.

Copyright

© 2024, Journal of Inflammatory Diseases. This open-access article is available under the Creative Commons Attribution-NonCommercial 4.0 (CC BY-NC 4.0) International License (https://creativecommons.org/licenses/by-nc/4.0/), which allows for the copying and redistribution of the material only for noncommercial purposes, provided that the original work is properly cited.

Similar Articles

31
Mar
2007

Evaluation of binding of FITC-prolactin conjugate to prolactin receptor

Majid sirati Sabet,
F Karami Tehrani

sirati Sabet M, Karami Tehrani F. Evaluation of binding of FITC-prolactin conjugate to prolactin receptor. J Inflamm Dis. 2024;10(4):e155258. doi:

30
Jun
2012

Comparison of Hormone Receptor Status in Primary and Recurrent Breast Cancer

Hamid Saeedi Saedi,
Mohammad-Reza Ghavam Nasir,
Soodabeh ShahidSales,
Ali Taghizadeh,
Nama Mohammadian

Saeedi Saedi H, Ghavam Nasir M, ShahidSales S, Taghizadeh A, Mohammadian N. Comparison of Hormone Receptor Status in Primary and Recurrent Breast Cancer. Int J Cancer Manag. 2012;5(2):e80803. doi:

28
Feb
2018

The Differences of Age, Tumor Grade, and Her2 Amplification in Estrogen and Progesterone Receptor Status in Patients with Breast Cancer

Elnaz Sheikhpour,
Shokouh Taghipour

Sheikhpour E, Taghipour S. The Differences of Age, Tumor Grade, and Her2 Amplification in Estrogen and Progesterone Receptor Status in Patients with Breast Cancer. Int J Cancer Manag. 2018;11(8):e9492. doi: https://doi.org/10.5812/ijcm.9492

26
Mar
2005

Effects of estradiol, progesterone and testosterone on proliferation of human breast cancer cell lines

M hashemi,
S Ghavami

hashemi M, Ghavami S. Effects of estradiol, progesterone and testosterone on proliferation of human breast cancer cell lines. Zahedan J Res Med Sci. 2005;7(1):e94974. doi:

6
Jun
2020
Comparison of ER, PR, Ki67 and HER-2/neu Reactivity Pattern with Patients’ Age, Histologic Grade, Tumor Size and Lymph Node Status in Invasive Ductal Breast Cancer

Comparison of ER, PR, Ki67 and HER-2/neu Reactivity Pattern with Patients’ Age, Histologic Grade, Tumor Size and Lymph Node Status in Invasive Ductal Breast Cancer

Mahsa Ahadi,
Motahareh Heibatollahi,
Sara Zahedifard

Ahadi M, Heibatollahi M, Zahedifard S. Comparison of ER, PR, Ki67 and HER-2/neu Reactivity Pattern with Patients’ Age, Histologic Grade, Tumor Size and Lymph Node Status in Invasive Ductal Breast Cancer. Int J Cancer Manag. 2020;13(6):e98325. doi: https://doi.org/10.5812/ijcm.98325

More by these authors

M Sirati SabetPubMedScholar
F Karami TehraniPubMedScholar
M TaghikhaniPubMedScholar
Share
Cited by
Metrics